Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- PD-L1 Antibody Atezolizumab in Japan PIII for 7 Indications: Chugai
July 22, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Kyowa Kirin Ups January-June Earnings Guidance
July 22, 2016
- Chugai Picks Galderma as Global Partner for Antibody Atopic Dermatitis Drug
July 22, 2016
- Maruho, Galderma Give Update on Their Comprehensive Collaboration
July 21, 2016
- Hiroki Kitamura Picked as New Yoshindo President
July 21, 2016
- 38% of Complete Response Patients Remained in Remission for 5-Plus Years: Adcetris PII
July 20, 2016
- US FDA OKs Once-Daily Belviq: Eisai
July 20, 2016
- FDA, EMA Accept Opdivo Filing for Head and Neck Cancer
July 20, 2016
- Bayer, Taisho Join Hands on Switch OTC Version of Claritin
July 19, 2016
- Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan
July 15, 2016
- AnGes MG, Osaka Univ. Team Up for Joint Research on Novel Drug Delivery System
July 15, 2016
- Takeda Launches Awareness Campaign for Inflammatory Bowel Disease in Europe, US
July 14, 2016
- Not Much Difference in Efficacy, Safety between 2 PCSK9 Inhibitors: Dr Teramoto of Teikyo University
July 14, 2016
- SymBio Earns Sales Milestone for Bendamustine from Taiwanese Firm
July 13, 2016
- “Limited Potential for Growth through Domestic Business Alone” Is Reason for Acquiring US Generic Maker: Nichi-Iko Pres.
July 13, 2016
- AnGes MG to Develop Chimera Decoy for World’s 1st Simultaneous Inhibition of Multiple Targets as Anti-Inflammatory Therapies
July 13, 2016
- Ono Gets Rights to Celyad’s Allogeneic CAR T-cell Therapy
July 12, 2016
- Kyorin to Copromote Allergy Drug Desloratadine with Kaken
July 12, 2016
- Medreich’s Japan-Bound Generics Plant in India Completed: Meiji
July 12, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…